Trial · NCT01483963
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline to Day 92 in Active Forward Flexion | Baseline, Day 92 | All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group) | degrees | MEAN |
| SECONDARY | Change From Baseline to Day 92 in Passive Forward Flexion | Baseline, Day 92 | All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group) | degrees | MEAN |
| SECONDARY | Change From Baseline to Day 92 in Active Abduction | Baseline, Day 92 | All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group) | degrees | MEAN |
| SECONDARY | Change From Baseline to Day 92 in Passive Abduction | Baseline, Day 92 | All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group) | degrees | MEAN |
| SECONDARY | Change From Baseline to Day 92 in Active External Rotation | Baseline, Day 92 | All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group) | degrees | MEAN |
| SECONDARY | Change From Baseline to Day 92 in Passive External Rotation | Baseline, Day 92 | All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group) | degrees | MEAN |
| SECONDARY | Change From Baseline to Day 92 in Active Internal Rotation | Baseline, Day 92 | All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group) | degrees | MEAN |
| SECONDARY | Change From Baseline to Day 92 in Passive Internal Rotation | Baseline, Day 92 | All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group) | degrees | MEAN |
| SECONDARY | Change From Baseline to Day 92 in American Shoulder and Elbow Surgeons (ASES) Composite Score | Baseline, Day 92 | All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group) | units on a scale | MEAN |
| SECONDARY | Change From Baseline to Day 92 in ASES Pain Subscale | Baseline, Day 92 | All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group) | units on a scale | MEAN |
| SECONDARY | Change From Baseline to Day 92 in ASES Function Subscale | Baseline, Day 92 | All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group) | units on a scale | MEAN |
| SECONDARY | Subject Satisfaction With Treatment at Day 92 | Day 92 | All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group) | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Investigator Assessment of Improvement With Treatment at Day 92 | Day 92 | All participants who have a baseline AROM measurement of the affected shoulder and at least 1 measurement of AROM of the affected shoulder following the first administration of study drug (AA4500 groups) or post baseline (shoulder exercises only group) | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01483963/outcomes